{"id":"W4386784286","doi":"10.1158/1557-3265.aacrahns23-po-072","title":"Abstract PO-072: Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Durvalumab; Clinical endpoint; Thyroid cancer; Cancer; Internal medicine; Oncology; Clinical trial; Adverse effect; Response Evaluation Criteria in Solid Tumors; Thyroid; Phases of clinical research; Immunotherapy; Pembrolizumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006922091,0.0005251289,0.00194629,0.000807092,0.0001546726,0.001651505,0.0009312459,0.000747859,0.001659707],"category_scores_gemma":[0.003780322,0.000269622,0.00101006,0.00135827,0.0005432133,0.0009009994,0.0003555473,0.001661728,0.000523967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035113,"about_ca_system_score_gemma":0.001204589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00077378,"about_ca_topic_score_gemma":0.00137955,"domain_scores_codex":[0.9991059,0.0003751507,0.0001410394,0.0001219592,0.000200067,0.00005585703],"domain_scores_gemma":[0.9956151,0.00232857,0.0007335742,0.0001832927,0.0009673779,0.000172017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.007379554,0.0007134146,0.01341423,0.004259646,0.001613768,0.0002665347,0.0001211248,0.0008417514,0.01110174,0.0009355015,0.007152356,0.9522004],"study_design_scores_gemma":[0.01427137,0.08525997,0.1922268,0.0110759,0.016262,0.00586951,0.0008106653,0.006760575,0.03231158,0.003961936,0.6309572,0.000232517],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1145036,0.8662952,0.001578202,0.005296906,0.000454921,0.000270864,0.000857678,0.00008194582,0.01066061],"genre_scores_gemma":[0.4266354,0.5537012,0.004061813,0.006954664,0.001982289,0.0004722941,0.003140612,0.0000892599,0.00296255],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006922091,"threshold_uncertainty_score":0.03660798,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3937507872669719,"score_gpt":0.5837503913856752,"score_spread":0.1899996041187033,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}